Patents by Inventor Jean-Paul Behr

Jean-Paul Behr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10927371
    Abstract: The invention relates to cationic siRNAs, characterized in that they are double-stranded RNA fragments, grafted to the ends of which are oligocations, the number of cationic charges grafted being comparable to or greater than that of the anionic charges carried by the internucleoside phosphates of the RNA strands.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: February 23, 2021
    Assignees: Centre National De La Recherche Scientifique (CNRS), Universite De Strasbourg, Pollyplus Transfection
    Inventors: France Jean-Paul Behr, Mitsuharu Kotera, Nadege Pfender, Jean-Serge Remy
  • Patent number: 9676798
    Abstract: The invention relates to oligonucleotide-oligocation molecules AiBjH that can be synthetized via automated phosphoramidite chemistry having oligonucleotides moieties Ai and oligocations moieties Bj, wherein .Ai is an i-mer oligonucleotide residue, with i=5 to 50, where nucleotide A is an oligomer with naturally or non naturally occurring nucleobases and/or pentafuranosyl groups and/or native phosphodiester bonds, for example selected from the group comprising deoxyribo, ribo, locked (LNA) nucleotides as well as their chemical modifications or substitutions such as phosphorothioate, 2?-fluoro, 2?-O-alkyl, or a marker group such as a fluorescent agent, .Bj is a j-mer organic oligocation moiety, with j=1 to 50, where B is selected from the group comprising .—HPO3—R1—(X—R2n)n1—X—R3—O—, where R1, R2n and R3, identical or different, are lower alkylene, X is NH or NC(NH2)2, n varies from 1 to 5 and n1=2 to 20, .
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: June 13, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE STRASBOURG, POLYPLUS TRANSFECTION
    Inventors: Jean-Paul Behr, Mitsuharu Kotera, Benedicte Pons, Emilie Voirin, Jean-Serge Remy
  • Publication number: 20160280728
    Abstract: The invention relates to oligonucleotide-oligocation molecules AiBjH that can be synthetized via automated phosphoramidite chemistry having oligonucleotides moieties Ai and oligocations moieties Bj, wherein .Ai is an i-mer oligonucleotide residue, with i=5 to 50, where nucleotide A is an oligomer with naturally or non naturally occurring nucleobases and/or pentafuranosyl groups and/or native phosphodiester bonds, for example selected from the group comprising deoxyribo, ribo, locked (LNA) nucleotides as well as their chemical modifications or substitutions such as phosphorothioate, 2?-fluoro, 2?-O-alkyl, or a marker group such as a fluorescent agent, .Bj is a j-mer organic oligocation moiety, with j=1 to 50, where B is selected from the group comprising .—HPO3—R1—(X—R2n)n1—X—R3—O—, where R1, R2n and R3, identical or different, are lower alkylene, X is NH or NC(NH2)2, n varies from 1 to 5 and n1=2 to 20, .
    Type: Application
    Filed: June 22, 2015
    Publication date: September 29, 2016
    Inventors: Jean-Paul BEHR, Mitsuharu KOTERA, Benedicte PONS, Emilie VOIRIN, Jean-Serge REMY
  • Patent number: 9243248
    Abstract: The invention relates to compositions comprising double-stranded oligonucleotides of identical or different sequences and/or length, said oligonucleotides having sequences 3?N1N2 . . . Ni-1Ni . . . Nj5? wherein—3?Ni . . . Nj5? is half of a double-stranded 19-28 mer oligonucleotide of sequence complementary to a target nucleic acid sequence present in a living cell, and—3?N1 . . . Ni-15? is a 3-50 mer overhang of sequence allowing oligomerization of said double-stranded oligonucleotide. Compositions of transfection comprising said oligonucleotide compositions and there used for therapeutical application.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: January 26, 2016
    Assignee: POLYPLUS-TRANSFECTION SA
    Inventors: Jean-Paul Behr, Anne-Laure Bolcato Bellemin, Patrick Erbacher
  • Patent number: 9090648
    Abstract: The invention relates to oligonucleotide-oligocation molecules AiBjH that can be synthetized via automated phosphoramidite chemistry having oligonucleotides moieties Ai and oligocations moieties Bj, wherein •Ai is an i-mer oligonucleotide residue, with i=5 to 50, where nucleotide A is an oligomer with naturally or non naturally occurring nucleobases and/or pentafuranosyl groups and/or native phosphodiester bonds, for example selected from the group comprising deoxyribo, ribo, locked (LNA) nucleotides as well as their chemical modifications or substitutions such as phosphorothioate, 2?-fluoro, 2?-O-alkyl, or a marker group such as a fluorescent agent, •Bj is a j-mer organic oligocation moiety, with j=1 to 50, where B is selected from the group comprising •—HPO3—R1—(X—R2n)n1—X—R3—O—, where R1, R2n and R3, identical or different, are lower alkylene, X is NH or NC(NH2)2, n varies from 1 to 5 and n1=2 to 20, •—HPO3—R4—CH(R5X1)—R6—O—, where R4 is lower alkylene, R5 and R6, identical or different, are lower alkylene
    Type: Grant
    Filed: December 14, 2006
    Date of Patent: July 28, 2015
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE STRASBOURG, POLYPLUS TRANSFECTION
    Inventors: Jean-Paul Behr, Mitsuharu Kotera, Bénédicte Pons, Emilie Voirin, Jean-Serge Remy
  • Publication number: 20140343125
    Abstract: The invention relates to compositions comprising double-stranded oligonucleotides of identical or different sequences and/or length, said oligonucleotides having sequences 3?N1N2 . . . Ni-1Ni . . . Nj5? wherein—3?Ni . . . Nj5? is half of a double-stranded 19-28 mer oligonucleotide of sequence complementary to a target nucleic acid sequence present in a living cell, and—3?N1 . . . Ni-15? is a 3-50 mer overhang of sequence allowing oligomerisation of said double-stranded oligonucleotide. Compositions of transfection comprising said oligonucleotide compositions and there used for therapeutical application.
    Type: Application
    Filed: July 1, 2014
    Publication date: November 20, 2014
    Inventors: Jean-Paul BEHR, Anne-Laure Bolcato Bellemin, Patrick Erbacher
  • Patent number: 8802640
    Abstract: The invention relates to compositions comprising double-stranded oligonucleotides of identical or different sequences and/or length, said oligonucleotides having sequences 3?N1N2 . . . Ni-1Ni . . . Nj5? wherein—3?Ni . . . Nj5? is half of a double-stranded 19-28mer oligonucleotide of sequence complementary to a target nucleic acid sequence present in a living cell, and—3?N1 . . . Ni-15? is a 3-50mer overhang of sequence allowing oligomerization of said double-stranded oligonucleotide. Compositions of transfection comprising said oligonucleotide compositions and there used for therapeutical application.
    Type: Grant
    Filed: June 1, 2006
    Date of Patent: August 12, 2014
    Assignee: Polyplus-Transfection SA
    Inventors: Jean-Paul Behr, Anne-Laure Bolcato Bellemin, Patrick Erbacher
  • Patent number: 8399422
    Abstract: The invention relates to compositions of transfection comprising an oligonucleotide and an amphiphilic cationic molecule of formula (I) wherein, —X is N—R1, S or O, R1 being a C1-C4 alkyl radical or an hydroxylated C3-C6 alkyl radical, R2 and R3, identical or different, represent H or a C1-C4 alkyl radical, or R2 and R3 are linked together to form a saturated or unsaturated cycle or a heterocycle having 5 or 6 elements, E is a C1-C5 alkyl spacer, R4 and R5, identical or different, represent saturated or unsaturated, linear or branched, C10-C36 hydrocarbon or fluorocarbon chains, optionally comprising C3-C6 cycloalkyl, A? is a biocompatible anion. The invention relates to compositions active for oligonucleotides delivery into eukaryotic cells in culture, ex vivo or in vivo. The invention relates to compositions of transfection comprising an oligonucleotide active for RNA interference. Such compositions can be used as tools for biological studies or as drugs for therapies.
    Type: Grant
    Filed: April 5, 2007
    Date of Patent: March 19, 2013
    Assignee: Polyplus-Transfection
    Inventors: Patrick Neuberg, Anne-Laure Bolcato Bellemin, Jean-Paul Behr, Patrick Erbacher
  • Publication number: 20110118331
    Abstract: The invention relates to cationic siRNAs, characterized in that they are double-stranded RNA fragments, grafted to the ends of which are oligocations, the number of cationic charges grafted being comparable to or greater than that of the anionic charges carried by the internucleoside phosphates of the RNA strands.
    Type: Application
    Filed: January 30, 2009
    Publication date: May 19, 2011
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: France Jean-Paul Behr, Mitsuharu Kotera, Nadege Pfender, Jean-Serge Remy
  • Publication number: 20100048672
    Abstract: The invention relates to compositions of transfection comprising an oligonucleotide and an amphiphilic cationic molecule of formula (I) wherein, —X is N—R1, S or O, R1 being a C1-C4 alkyl radical or an hydroxylated C3-C6 alkyl radical, R2 and R3, identical or different, represent H or a C1-C4 alkyl radical, or R2 and R3 are linked together to form a saturated or unsaturated cycle or a heterocycle having 5 or 6 elements, E is a C1-C5 alkyl spacer, R4 and R5, identical or different, represent saturated or unsaturated, linear or branched, C10-C36 hydrocarbon or fluorocarbon chains, optionally comprising C3-C6 cycloalkyl, A- is a biocompatible anion. The invention relates to compositions active for oligonucleotides delivery into eukaryotic cells in culture, ex vivo or in vivo. The invention relates to compositions of transfection comprising an oligonucleotide active for RNA interference. Such compositions can be used as tools for biological studies or as drugs for therapies.
    Type: Application
    Filed: April 5, 2007
    Publication date: February 25, 2010
    Applicant: POLYPLUS-TRANSFECTION
    Inventors: Patrick Neuberg, Anne-Laure Bolcato Bellemin, Jean-Paul Behr, Patrick Erbacher
  • Publication number: 20090069262
    Abstract: The invention relates to oligonucleotide-oligocation molecules AiBjH that can be synthetized via automated phosphoramidite chemistry having oligonucleotides moieties Ai and oligocations moieties Bj, wherein. Ai is an i-mer oligonucleotide residue, with i=5 to 50, where nucleotide A is an oligomer with naturally or non naturally occurring nucleobases and/or pentafuranosyl groups and/or native phosphodiester bonds, for example selected from the group comprising deoxyribo, ribo, locked (LNA) nucleotides as well as their chemical modifications or substitutions such as phosphorothioate, 2?-fluoro, 2?-O-alkyl, or a marker group such as a fluorescent agent, Bj is a j-mer organic oligocation moiety, with j=1 to 50, where B is selected from the group comprising .—HPO3—R1—(X—R2n)n1—X—R3—O—, where R1, R2n and R3, identical or different, are lower alkylene, X is NH or NC(NH2)2, n varies from 1 to 5 and n1=2 to 20, .
    Type: Application
    Filed: December 14, 2006
    Publication date: March 12, 2009
    Inventors: Jean-Paul Behr, Mitsuharu Kotera, Benedicte Pons, Emilie Voirin, Jean-Serge Remy
  • Publication number: 20080153772
    Abstract: The invention relates to compositions comprising double-stranded oligonucleotides of identical or different sequences and/or length, said oligonucleotides having sequences 3?N1N2 . . . Ni?1Ni . . . Nj5? wherein—3Ni . . . Nj5? is half of a double-stranded 19-28 mer oligonucleotide of sequence complementary to a target nucleic acid sequence present in a living cell, and—3?N1 . . . Ni?15? is a 3-50 mer overhang of sequence allowing oligomerisation of said double-stranded oligonucleotide. Compositions of transfection comprising said oligonucleotide compositions and there used for therapeutical application.
    Type: Application
    Filed: June 1, 2006
    Publication date: June 26, 2008
    Inventors: Jean-Paul Behr, Anne-Laure Bolcato Bellemin, Patrick Erbacher
  • Publication number: 20030100113
    Abstract: A non-viral transfection vector which is to be delivered into the nucleus of a cell comprises a DNA molecule that is equipped with 1 to 25 NLS conjugates. Each conjugate comprises a nuclear localization signal (NLS) covalently linked to an oligonucleotide. The NLS conjugate may be covalently linked to one or both termini of a linear DNA molecule, associated with a plasmid DNA molecule by forming a triple helix, or inserted in a plasmid DNA molecule by strand invasion. The transfection vector is useful for gene therapy applications.
    Type: Application
    Filed: August 22, 2002
    Publication date: May 29, 2003
    Applicant: UNIVERSITE LOUIS PASTEUR DE STRASBOURG
    Inventors: Jean Paul Behr, Pascale Belguise-Valladier, Maria-Antonietta Zanta
  • Patent number: 6172048
    Abstract: The present invention relates to compositions comprising at least one nucleic acid and one lipopolyamine, and their utilisation in gene therapy, particularly for the transfert in vivo of nucleic acids.
    Type: Grant
    Filed: September 25, 1998
    Date of Patent: January 9, 2001
    Assignee: Aventis Pharma S.A.
    Inventors: Jean-Paul Behr, Barbara Demeneix, Daniel Scherman, Bertrand Schwartz, Jean-Serge Remy
  • Patent number: 6013240
    Abstract: Compositions containing one or more nucleic acids and cationic polymers, and their use in gene therapy, particularly for in vivo nucleic acid transfer.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: January 11, 2000
    Assignee: Rhone-Poulenc Rorer SA
    Inventors: Jean-Paul Behr, Barbara Demeneix, Franck Lezoualch, Mojgan Mergny, Daniel Scherman, Otmane Boussif
  • Patent number: 5846947
    Abstract: The present invention relates to compositions comprising at least one nucleic acid and one lipopolyamine, and their utilisation in gene therapy, particularly for the transfert in vivo of nucleic acids.
    Type: Grant
    Filed: July 10, 1996
    Date of Patent: December 8, 1998
    Assignee: Rhone-Poulenc Rorer SA
    Inventors: Jean-Paul Behr, Barbara Demeneix, Daniel Scherman, Bertrand Schwartz, Jean-Serge Remy
  • Patent number: 5616745
    Abstract: New lipopolyamines of general formula (I), their salts, their preparation and their use. ##STR1## n=1 to 5 and m=2 to 6 R represents a radical ##STR2## (R.sub.1 and R.sub.2 : aliphatic radical containing 12 to 22 carbon atoms; R: hydrogen atom or alkyl radical optionally substituted with phenyl), or a radical ##STR3## (X=CH.sub.2, CO; R.sub.3 and R.sub.4 aliphatic radical containing 11 to 21 carbon atoms), their preparation and their use.The lipopolyamines of general formula (I) are especially useful as vectors for the transfection of eukaryotic cells.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 1, 1997
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Jean-Paul Behr, Jean-Philippe Loeffler
  • Patent number: 5476962
    Abstract: Intermediate compounds useful for producing transfecting lipopolyamines, comprising: ##STR1## wherein m is an integer between 2 and 6 inclusive, wherein n is an integer between 2 and 5 inclusive, wherein R.sub.5 represents a hydrogen atom or a carboxyl radical but no more than one R.sub.5 represents a carboxyl, the values of m in the different fragments (CH).sub.m may be identical or different, and wherein the symbol Z R.sub.5 represent a group protecting the amine function.
    Type: Grant
    Filed: February 3, 1994
    Date of Patent: December 19, 1995
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Jean-Paul Behr, Jean-Philippe Loeffler
  • Patent number: 5171678
    Abstract: New lipopolyamines of general formula (I), their salts, their preparation and their use. ##STR1## n=1 to 5 and m=2 to 6; R represents a radical ##STR2## (R.sub.1 and R.sub.2 : aliphatic radical containing 12 to 22 carbon atoms; R: hydrogen atom or alkyl radical optionally substituted with phenyl), or a radical ##STR3## (X=CH.sub.2, CO; R.sub.3 and R.sub.4 aliphatic radical containing 11 to 21 carbon atoms), their preparation and their use.The lipopolyamines of general formula (I) are especially useful as vectors for the transfection of eukaryotic cells.
    Type: Grant
    Filed: April 17, 1990
    Date of Patent: December 15, 1992
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Jean-Paul Behr, Jean-Philippe Loeffler